Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6103469 | 1.00 | F10 (0.78) | F10 | |
| SCHEMBL6105641 | 0.90 | F10 (0.72) | F10 | |
| SCHEMBL6105634 | 0.90 | F10 (0.72) | F10 | |
| SCHEMBL6103778 | 0.89 | F10 (0.62) | F10 | |
| SCHEMBL6103783 | 0.89 | F10 (0.62) | F10 | |
| SCHEMBL6106848 | 0.88 | F10 (0.79) | F10 | |
| SCHEMBL6106840 | 0.88 | F10 (0.79) | F10 | |
| SCHEMBL4029786 | 0.87 | F10 (1.00) | F10 | |
| SCHEMBL4030521 | 0.87 | F10 (1.00) | F10 | |
| SCHEMBL6105426 | 0.87 | F10 (0.58) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135515-A1 | Heterocyclic amides and their use treating thromboembolic diseases and tumors | MERCK PATENT GMBH (DE) | 2006-06-22 | — | — | US | claimed |
| US-20060135515-A1 | Heterocyclic amides and their use treating thromboembolic diseases and tumors | MERCK PATENT GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
| WO-2004035039-A1 | HETEROCYCLIC AMIDES AND THEIR USE IN TREATING THROMBOEMBOLIC DISEASES AND TUMORS | MERCK PATENT GMBH (DE) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135515-A1 | Heterocyclic amides and their use treating thromboembolic diseases and tumors | F2, F11, F12 | F10 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.